1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Neoplasm Malignant: new trials by email Literature Review of Neoplasm Malignant trials Research Report on Neoplasm Malignant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) Pembrolizumab, Belzutifan, Lenvatinib - Neoplasm Malignant | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 730 | 2021-08-18 | 2025-04-06 |
Neoplasms (1)
belzutifan (1) · lenvatinib (1) · pembrolizumab (1)
Australia (1) · Belgium (1) · Chile (1) · France (1) · Israel (1) · Netherlands (1) · New Zealand (1) · South Korea (1) · Spain (1) · United States (1)
2023 (1)